Citrulline and anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis

By Yamada Ryo   Suzuki Akari   Yamamoto Kazuhiko  

Future Rheumatology, Vol. 1, Iss. 2, 2006-04 ,pp. : 249-258

Future Medicine

Access to resources Recommend Favorite

Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis

By Grootenboer-Mignot S   Nicaise-Roland P   Delaunay C   Meyer O   Chollet-Martin S   Labarre C  

Scandinavian Journal of Rheumatology, Vol. 33, Iss. 4, 2004-07 ,pp. : 218-220

Informa Healthcare

Access to resources Recommend Favorite

Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gender, and tabagism in rheumatoid arthritis patients from southern Brazil

By Goeldner Isabela  

Clinical Rheumatology, Vol. 30, Iss. 7, 2011-07 ,pp. : 975-980

Springer Publishing Company

Access to resources Recommend Favorite

Anti-cyclic citrullinated peptide antibodies do not reflect self-reported disability and physical health in patients with rheumatoid arthritis of less than 5 years of duration

By Poulsen Chalotte   Jacobsen Søren   Frisch Morten   Frederiksen Kirsten   Johansen Christoffer  

Rheumatology International, Vol. 33, Iss. 11, 2013-11 ,pp. : 2763-2772

Springer Publishing Company

Access to resources Recommend Favorite

Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis

By Mori Shunsuke   Hirose Jun   Yonemura Kensuke  

Clinical Rheumatology, Vol. 29, Iss. 12, 2010-12 ,pp. : 1357-1366

Springer Publishing Company

Access to resources Recommend Favorite